Patents by Inventor Francesca LAWSON

Francesca LAWSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of type 2 diabetes mellitus patients
    Patent number: 10159713
    Abstract: The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: December 25, 2018
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Rene Belder, Peter Johnston, Francesca Lawson, Lin Ping, Xiaodan Wei
  • Treatment of Type 2 Diabetes Mellitus Patients
    Publication number: 20180243379
    Abstract: The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 30, 2018
    Inventors: Rene Belder, Peter Johnston, Francesca Lawson, Lin Ping, Xiaodan Wei
  • Treatment of Type 2 Diabetes Mellitus Patients
    Publication number: 20160296601
    Abstract: The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
    Type: Application
    Filed: March 17, 2016
    Publication date: October 13, 2016
    Inventors: Rene Belder, Peter Johnston, Francesca Lawson, Lin Ping, Xiaodan Wei
  • SEMULOPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS RECEIVING CHEMOTHERAPY
    Publication number: 20120322759
    Abstract: The invention relates to an ultra-low molecular weight heparin with an average molecular weight of 2000 to 3000 Daltons, an anti-FXa activity of about 160 U/mg and an anti-FIIa activity of about 2 U/mg, in particular semuloparin, for use as an antithrombotic agent for the prophylaxis of venous thromboembolism in cancer patients receiving chemotherapy for locally advanced or metastatic solid tumors, more specifically in patients receiving chemotherapy for locally advanced or metastatic pancreatic or lung cancer, or for locally advanced or metastatic solid tumors with a VTE risk score equal to or greater than 3.
    Type: Application
    Filed: May 11, 2012
    Publication date: December 20, 2012
    Applicant: AVENTIS PHARMA SA
    Inventors: Umesh CHAUDHARI, Dominique DESTREE, Francesca LAWSON, Guillaume LECORPS